The application of health technology assessment in osteoporosis

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 28, Issue 6, 2014, Pages 895-910

  Kanis, John A ^a   Hiligsmann, Mickaël ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Burden of disease; Cost effectiveness; Economic evaluation; Health technology assessment; Osteoporosis; Treatment

Indexed keywords

ALENDRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; RALOXIFENE; RISEDRONIC ACID; STRONTIUM;

ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; ECONOMIC EVALUATION; FRAGILITY FRACTURE; OSTEOPOROSIS; RESOURCE ALLOCATION; SENSITIVITY ANALYSIS; COST BENEFIT ANALYSIS; COST OF ILLNESS; ECONOMICS; HUMAN; STATISTICS AND NUMERICAL DATA;

COST OF ILLNESS; COST-BENEFIT ANALYSIS; HUMANS; OSTEOPOROSIS; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 84927971909     PISSN: 1521690X     EISSN: 15321908     Source Type: Journal    
DOI: 10.1016/j.beem.2014.04.001     Document Type: Review

References (91)

1. Hiligsmann M, Kanis JA, Compston J, et al. Health technology assessment in osteoporosis. Calcif Tissue Int 2013; 93: 1-14.
2. Goodman C. HTA 101. Introduction to health technology assessment. http://www.nlm.nih.gov/nichsr/hta101/hta101.pdf [accessed 01.04.12]
3. Jonsson E, Banta D. Management of health technologies: An international view. Br Med J 1999; 319. 1293-U42.
4. Banta D, Jonsson E. History of HTA: Introduction. Int J Technol Assess Health Care 2009; 25 (Suppl. 1) : 1-6.
5. Martelli F, La Torre G, Di Ghionno E, et al. Health technology assessment agencies: An international overview of organizational aspects. Int J Technol Assess Health Care 2007; 23: 414-24.
6. Oliver A, Mossialos E, Robinson R. Health technology assessment and its influence on health-care priority setting. Int J Technol Assess Health Care 2004; 20: 1-10.
7. Banta D, Oortwijn W. Health technology assessment and health care in the European Union. Int J Technol Assess Health Care 2000; 16: 626-35.
8. Hernlund E, Svedbom A, Ivergård M, et al. Osteoporosis in the european Union: Medical management, epidemiology and economic Burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA) . Archi Osteoporos 2013; 8: 136.
9. Svedbom A, Hernlund E, Ivergård M, et al., and the EU review panel of the IOF. Osteoporosis in the European Union: A compendium of country-specific reports. Arch Osteoporos 2013; 8: 137.
10. Kanis JA, Borgström F, Compston J, et al. SCOPE: A scorecard for osteoporosis in Europe. Archives Osteoporos 2013; 8: 144.
11. Kanis JA. Assessment of osteoporosis at the primary health-care level. Technical Report. UK: WHO Collaborating Centre, University of Sheffield; 2008., http://www.shef.ac.uk/FRAX/pdfs/WHO-Technical-Report.pdf [accessed 07.03.14].
12. Compston J, Cooper A, Cooper C, et al., on behalf of the National Osteoporosis Guideline Group (NOGG) . Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 2009; 62: 105-8.
13. Lekawasam S, Adachi JD, Agnusdei D, et al., for the Joint IOF-ECTS GIO Guidelines Working Group. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int 2012; 23: 2257-76.
14. Kanis JA, McCloskey EV, Johansson H, et al., on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation ( IOF) . European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2013; 24: 23-57.
15. Zethraeus N, Borgström F, Ström O, et al. Cost-effectiveness of the treatment and prevention of osteoporosis-A review of the literature and a reference model. Osteoporos Int 2007; 18: 9-23.
16. Ström O, Borgstrom F, Zethraeus N, et al. Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden. Acta Orthop Scand 2008; 79: 269-80.
17. Raftery J. NICE: Faster access to modern treatments? Analysis of guidance on health technologies. Br Med J 2001; 323: 1300-3.
18. World Health Organization. Macroeconomics and health: Investing in health for economic development. Report of the Commission on Macroeconomics and Health [accessed 10.04.12], http://whqlibdoc.who.int/publications/2001/924154550x.pdf; 2011.
19. Murray C, Lopez A. Global and regional descriptive epidemiology of disability. Incidence, prevalence, health expectancies and years lived with disability. In: Murray C, Lopez A, editors. The global burden of disease: A comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Cambridge: Cambridge University Press; 1996. pp. 201-46.
20. Eichler HG, Kong SX, Gerth WC, et al. Use of cost-effectiveness analysis in health-care resource allocation decisionmaking: How are cost-effectiveness thresholds expected to emerge? Value Health 2004; 7: 518-28.
21. Borgstrom F, Sobocki P, Strom O, et al. The societal burden of osteoporosis in Sweden. Bone 2007; 40: 1602-9.
22. Ström O, Borgström F, Kanis J, et al. Osteoporosis: Burden, health care provision and opportunities in the European Union. Arch Osteoporos 2011; 6: 59-155.
23. Ivergård M, Ström O, Borgström F, et al. Identifying cost-effective treatment with raloxifene in postmenopausal women using risk algorithms for fractures and invasive breast cancer. Bone 2010; 47: 966-74.
24. Kanis JA, Odén A, McCloskey EV, et al., on behalf of the IOF Working Group on Epidemiology and Quality of Life. A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int 2012; 23: 2239-56.
25. Johnell O, Borgstrom F, Jonsson B, et al. Latitude, socioeconomic prosperity, mobile phones and hip fracture risk. Osteoporos Int 2007; 18: 333-7.
26. UN. Population Division of the Department of Economic and Social Affairs of the United Nations Secretariat. World population prospects: The 2010 revision [accessed 16.11.12], http://esa.un.org/unpd/wpp/index.htm; 2010.
27. Cooper C, Cole ZA, Holroyd CR, et al., and the IOF CSA Working Group on Fracture Epidemiology. Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int 2011; 22: 1277-88.
28. Gullberg B, Johnell O, Kanis JA. World-wide projections for hip fracture. Osteoporos Int 1997; 7: 407-13.
29. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: Now and the future. Lancet 2011; 377: 1276-87.
30. Cooper C, Reginster JY, Cortet B, et al. Long-term treatment of osteoporosis in postmenopausal women: A review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF) . Curr Med Res Opin 2012; 28: 475-91.
31. Mazziotti G, Bilezikian J, Canalis E, et al. New understanding and treatments for osteoporosis. Endocrinology 2012; 41: 58-69.
32. Taylor RS, Drummond MF, Salkeld G, et al. Inclusion of cost effectiveness in licensing requirements of new drugs: The fourth hurdle. Br Med J 2004; 329: 972-5.
33. Drummond M, Jonsson B, Rutten F. The role of economic evaluation in the pricing and reimbursement of medicines. Health Policy 1997; 40: 199-215.
34. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the fracture intervention trial. J Am Med Assoc 1998; 280: 2077-82.
35. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348: 1535-41.
36. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2011; 344: 333-40.
37. Drummond M, Sculpher M, O'Brien B, et al. Methods for the economic evaluation of health care programmes. 3th ed. New-York: Oxford University Press; 2007.
38. Kanis JA, Cooper C, Hiligsmann M, et al. Partial adherence: A new perspective on health economic assessment in osteoporosis. Osteoporos Int 2011; 22: 2565-73.
39. Palmer S, Byford S, Raftery J. Economics notes: Types of economic evaluation. Br Med J 1999; 318: 1349.
40. Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. 2nd ed. New-York: Oxford University Press; 2007.
41. Brennan A, Akehurst R. Modelling in health economic evaluation. What is its place? What is its value? Pharmacoeconomics 2000; 17: 445-59.
42. Buxton MJ, Drummond MF, Van Hout BA, et al. Modelling in economic evaluation: An unavoidable fact of life. Health Econ 1997; 6: 217-27.
43. Sonnenberg FA, Beck JR. Markov models in medical decision making: A practical guide. Med Decis Making 1993; 13: 322-38.
44. Hiligsmann M, Ethgen O, Bruyere O, et al. Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis. Value Health 2009; 12: 687-96.
45. Vemer P, Krabbe PF, Feenstra TL, et al. Improving model validation in health technology assessment: Comments on guidelines of the ISPOR-SMDM modeling good research practices task force. Value Health 2013; 16: 1106-7.
46. Fenwick E, O'Brien BJ, Briggs A. Cost-effectiveness acceptability curves-facts, fallacies and frequently asked questions. Health Econ 2004; 13: 405-15.
47. Kanis JA, Adams J, Borgström F, et al. The cost-effectiveness of alendronate in the management of osteoporosis. Bone 2008; 42: 4-15.
48. Zethraeus N, Ben SedrineW, Caulin F, et al. Models for assessing the cost-effectiveness of the treatment and prevention of osteoporosis. Osteoporos Int 2002; 13: 841-57.
49. Muller D, Pulm J, Gandjour A. Cost-effectiveness of different strategies for selecting and treating individuals at increased risk of osteoporosis or osteopenia: A systematic review. Value Health 2012; 15: 284-98.
50. Hiligsmann M, Bruyere O, Reginster JY. Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women. Osteoporos Int 2010; 21: 157-65.
51. Hiligsmann M, Reginster JY. Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women. Bone 2010; 47: 34-40.
52. Hiligsmann M, Vanoverberghe M, Neuprez A, et al. Cost-effectiveness of strontium ranelate for the prevention and treatment of osteoporosis. Expert Rev Pharmacoecon Outcomes Res 2010; 10: 359-66.
53. Hiligsmann M, McGowan B, Bennett KJY, et al. The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland. Value Health 2012; 15: 604-12.
54. Borgström F, Carlsson A, Sintonen H, et al. The cost-effectiveness of risedronate in the treatment of osteoporosis: An international perspective. Osteoporos Int 2006; 17: 996-1007.
55. Borgström F, Zethraeus N, Johnell O, et al. Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporos Int 2006; 17: 637-50.
56. Borgström F, Jönsson B, Ström O, et al. An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: Based on the results of the SOTI and TROPOS trials. Osteoporos Int 2006; 17: 1781-93.
57. Si L, Winzenberg TM, Palmer AJ. A systematic review of models used in cost-effectiveness analyses of preventing osteoporotic fractures. Osteoporos Int 2013; 25: 51-60.
58. Fleurence RL, Iglesias CP, Torgerson DJ. Economic evaluations of interventions for the prevention and treatment of osteoporosis: A structured review of the literature. Osteoporos Int 2006; 17: 29-40.
59. Fleurence RL, Iglesias CP, Johnson JM. The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: A structured review of the literature. Pharmacoeconomics 2007; 25: 913-33.
60. Schousboe JT. Cost effectiveness of screen-and-treat strategies for low bone mineral density: How do we screen, who do we screen and who do we treat? Appl Health Econ Health Policy 2008; 6: 1-18.
61. Ström O, Borgström F, Sen SS, et al. Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries-an economic evaluation based on the fracture intervention trial. Osteoporos Int 2007; 18: 1047-61.
62. Borgström F, Johnell O, Kanis JA, et al. Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: An economic evaluation based on the MORE study. Pharmacoeconomics 2004; 22: 1153-65.
63. Borgström F, Ström O, Coelho J, et al. The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX. Osteoporos Int 2010; 21: 495-505.
64. Borgström F, Strom O, Coelho J, et al. The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis. Osteoporos Int 2010; 21: 339-50.
65. Hiligsmann M, Bruyere O, Reginster JY. Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years. Bone 2010; 46: 440-6.
66. Jönsson B, Ström O, Eisman JA, et al. Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int 2011; 22: 967-82.
67. Kanis JA, Borgstrom F, Johnell O, et al. Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. Osteoporos Int 2004; 15: 862-71.
68. Borgstrom F, Johnell O, Kanis JA, et al. At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis. Osteoporos Int 2006; 17: 1459-71.
69. Hiligsmann M, Reginster JY. Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium. Pharmacoeconomics 2011; 29: 895-911.
70. Akehurst R, Brereton N, Ariely R, et al. The cost effectiveness of zoledronic acid 5 mg for the management of postmenopausal osteoporosis in women with prior fractures: Evidence from Finland, Norway and the Netherlands. J Med Econ 2011; 14: 53-64.
71. Cranney A, Guyatt G, Griffith L, et al. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of metaanalyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002; 23: 570-8.
72. Strom O, Borgstrom F, Kanis JA, et al. Incorporating adherence into health economic modelling of osteoporosis. Osteoporos Int 2009; 20: 23-34.
73. Hiligsmann M, Rabenda V, Bruyere O, et al. The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients. Health Policy 2010; 96: 170-7.
74. Hiligsmann M, Boonen A, Rabenda V, et al. The importance of integrating medication adherence into pharmacoeconomic analyses: The example of osteoporosis. Expert Rev Pharmacoecon Outcomes Res 2012; 12: 159-66.
75. Landfeldt E, Lundkvist J, Strom O. The societal burden of poor persistence to treatment of osteoporosis in Sweden. Bone 2011; 48: 380-8.
76. Patrick AR, Schousboe JT, Losina E, et al. The economics of improving medication adherence in osteoporosis: Validation and application of a simulation model. J Clin Endocrinol Metab 2011; 96: 2762-70.
77. Kim K, Svedbom A, Luo X, Sutradhar S, Kanis JA. Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe using the FRAX algorithm. Osteoporos Int 2014; 25: 325-37.
78. Borgström F, Ström O, Kleman M, et al. Cost-effectiveness of bazedoxifene incorporating the FRAX- algorithm in a European perspective. Osteoporos Int 2011; 22: 955-65.
79. Ström O, Borgström F, Kleman M, et al. FRAX- and its applications in health economics-cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example. Bone 2010; 47: 430-7.
80. Ström O, Jönsson B, Kanis JA. Intervention thresholds for denosumab in the UK using a FRAX- based cost-effectiveness analysis. Osteoporos Int 2013; 24: 1491-502.
81. Kanis JA, McCloskey EV, Johansson H, et al. Development and use of FRAX in osteoporosis. Osteoporos Int 2010; 21: S407-13.
82. Kanis JA, Johansson H, Oden A, et al. A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX. Bone 2010; 47: 729-35.
83. Lippuner K, Johansson H, Borgström F, et al. Cost-effective intervention thresholds against osteoporotic fractures based on FRAX- in Switzerland. Osteoporos Int 2012; 23: 2579-89.
84. Kanis JA, McCloskey EV, Johansson H, et al. Case finding for the management of osteoporosis with FRAX-assessment and intervention thresholds for the UK. Osteoporos Int 2008; 19: 1395-408.
85. Kanis JA, Johansson H, Oden A, et al. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone 2009; 44: 1049-54.
86. McCloskey EV, Johansson H, Oden A, et al. Ten-year fracture probability identifies women who will benefit from clodronate therapy-additional results from a double blind, placebo controlled randomised study. Osteoporos Int 2009; 20: 811-8.
87. Kanis JA, Jönsson B, Odén A, et al. A meta-analysis of the effect of strontium ranelate on the risk of vertebral and nonvertebral fracture in postmenopausal osteoporosis and the interaction with FRAX. Osteoporos Int 2011; 22: 2347-55. With erratum Osteoporosis International 2011; 22: 2357-2358.
88. Hutton J, Trueman P, Facey K. Harmonization of evidence requirements for health technology assessment in reimbursement decision making. Int J Technol Assess Health Care 2008; 24: 511-7.
89. Drummond M, Barbieri M, Cook J, et al. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. Value Health 2009; 12: 409-18.
90. Drummond MF, Schwartz JS, Jonsson B, et al. Key principles for the improved conduct of health technology assessments for resource allocation decisions. Int J Technol Assess Health Care 2008; 24: 244-58 [discussion 2008; 24: 362-368].
91. Humphreys K, Piot P. Scientific evidence alone is not sufficient basis for health policy. Br Med J 2012; 344: E1316.